8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                    FORM 8-K
                                 CURRENT REPORT


     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


        Date of Report (Date of earliest event reported) August 20, 2007
                                                           -------------


                    SUNWIN INTERNATIONAL NEUTRACEUTICALS,INC.
             (Exact name of registrant as specified in its charter)


      Nevada                          033-10456                56-2416925
      ---------------------------- --------------------    -------------------
    (State or other jurisdiction        (Commission          (IRS Employer
       of incorporation)                 File Number)      Identification No.)



                  6 Youpeng Road, Qufu, Shandong, China 273100
                  --------------------------------------------
               (Address of principal executive offices) (Zip Code)


       Registrant's telephone number, including area code (86) 537-4424999



          (Former name or former address, if changed since last report)


                 Check the appropriate box below if the Form 8-K
                filing is intended to simultaneously satisfy the
              filing obligation of the registrant under any of the
           following provisions (see General Instruction A.2. below):

  [ ] Written communications pursuant to Rule 425 under the Securities Act
      (17 CFR 230.425)

  [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
      (17 CFR 240.14a-12)

  [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

  [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))



Item 7.01         REGULATION FD DISCLOSURE

             On August 20, 2007, we issued a press release regarding a corporate
update and our business outlook for fiscal year 2008. The press release is
attached hereto as Exhibit 99.1 and incorporated herein by reference.

             The information contained in the press release attached hereto is
being furnished and shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise
subject to the liability of that Section, and shall not be incorporated by
reference into any registration statement or other document filed under the
Securities Act of 1933, as amended, or the Exchange Act, except as shall be
expressly set forth by specific reference in such filing.


Item  9.01.       FINANCIAL STATEMENTS AND EXHIBITS

(d)      Exhibits

99.1     Press Release dated August 20, 2007.



                                                              SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                     SUNWIN INTERNATIONAL NEUTRACEUTICALS, INC.



Date:  August 20, 2007                    By:   /s/ Dongdong Lin
                                               --------------------------
                                                Dongdong Lin
                                                Chief Executive Officer

EX-99

              Sunwin International Neutraceuticals Issues Corporate
              Update for Business Outlook for Fiscal Year of 2008

Qufu, China, August 20, 2007 - (Market Wire) - Sunwin International
Neutraceuticals, Inc. (OTCBB: SUWN), a leader in the production and distribution
of Chinese herbs, veterinary medicines and one of the world's leading producers
and distributors of all natural, zero calorie Stevia in China, today announced
management's recap of fiscal 2007 and its business outlook for fiscal year ended
April 30, 2008.

In the fiscal year 2007, we made significant capital investments for the future
of our company and achieved several major milestones as follows:

- -    Completed $4.2 million private equity offering.

- -    Completed  construction  of new stevia  manufacturing  facilities.  The new
     facilities  will  yield  1 ton  of  premium  stevia  (A360)  per  day or an
     estimated 300 tons per year.

- -    Launched  and  branded our  OnlySweet  product  lines in the U.S.  markets.
     OnlySweet products are currently available over 3,000 grocery stores in the
     U.S.

- -    Developed 5 new Chinese herb-based  products.  We anticipate these products
     will receive  approval  from the  government  for sale in China this fiscal
     year.
- -    Developed  new  veterinary  feeds  that are based on  residue  from  stevia
     production.  The new  veterinary  feeds will be ready for  marketing in the
     2008 fiscal year.

We believe the deployment of our capital for investing in the future will yield
significant rewards in the years to come for our company and its shareholders.
We are confident that we have laid a strong foundation for substantial growth in
the fiscal year of 2008.

Management currently sees the following fiscal 2008 outlook for its divisions as
follows:

     -    Stevia Production:  We expect to reach a production capacity of 500 to
          600 tons of  stevia  in  fiscal  2008.  That  translates  to $15 to 18
          million in annual  revenues  with an estimated  15% net profit  margin
          should that  production be sold out at current  price  levels.  We are
          also in the early planning stages to increase  capacity in fiscal 2008
          by adding one additional facility capable of producing 150 tons (A380)
          stevia. When complete,  that capacity if sold at current price levels,
          would  translates  into $12  million in annual  revenues  with 20% net
          profit margin.

     -    OnlySweet Products:  We expect OnlySweet products will be available in
          over 6,000 to 7,000  grocery  stores in the U.S.  during  fiscal 2008.
          Initial sales response is very  encouraging and we estimate that sales
          could reach as high as a $12 million annualized run rate by the end of
          fiscal  2008  subject to the  timing of store  launches  and  customer
          acceptance. We feel confident that profit margins for this line should
          be in the 30% range.

     -    Veterinary  Medicine and Feeds:  We expect our  medicines and feeds to
          experience  growth  of about  30% to  approximately  $4.2  million  in
          revenues  with 9% net  profit  in  fiscal  2008.  We  expect to launch
          stevia-based  veterinary  feeds in the coming month and depending upon
          timing of launch and acceptance the revenue contribution could reach a
          run  rate  of  $12  million  by the  end  of  this  fiscal  year  with
          significantly higher gross margins.

     -    Chinese  Herb  Medicine:  We  anticipate  significant  growth  in this
          division subject to the timing of approvals in China. Growth from this
          division could be as high as 50% which could yield  approximately $5.4
          million in  revenues  with 10% net profit  margins in the fiscal  year
          should approvals and launches happen as we project.

Laiwang Zhang, President, and Chairman of Sunwin International Neutraceuticals,
commented "We have made strong financial commitments in fiscal 2007 which we
believe will surface in the company's 2008 performance. While these investments
contributed to a decline in our overall results for 2007, we are confident that
they will significantly enhance our prospects for fiscal year 2008 and beyond.
We continue to develop new products in order to expand our offerings in the
market place and are confident that fiscal 2008 will be a strong year based on
the decisions made in 2007."

About Sunwin International Neutraceuticals, Inc.

Sunwin International Neutraceuticals (OTCBB: SUWN) engages in the areas of
essential traditional Chinese medicine, zero calorie natural sweetener (Stevia),
and veterinary medicines and feeds prepared from herbal ingredients. As an
industry leader in agricultural processing, Sunwin has built an integrated
global firm with the sourcing and production capabilities to meet the needs of
consumers throughout the world. Sunwin also makes such value-added products as
specialty veterinary food ingredients and specialty feed ingredients. For more
info about Sunwin, please visit http://www.sunwin.biz

About OnlySweet(TM)

OnlySweet(TM) is a proprietary product blended with Stevioside (stevia), a
natural sweetener, extracted from the leaves of the Stevia rebaudiana plant.
OnlySweet(TM) is distributed through Sunwin Stevia International Corp. It is
used as a food additive in a wide variety of products, such as beverages,
pastries, dairy products, confections, and medicinal products in Japan, China,
Malaysia, Israel, South Korea, Brazil, and other countries. In the United
States, OnlySweet(TM) is a dietary supplement sold in boxes of 100 and 200
sachets. It has zero calories and does not significantly alter blood sugar
levels. OnlySweet(TM) is unique because its stevia only comes directly from
Sunwin International Neutraceuticals (OTCBB: SUWN), one of the world's largest
stevia manufacturers, assuring consistency and purity.

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations or beliefs, including, but not
limited to, statements concerning the Company's operations, financial
performance and, condition. For this purpose, statements that are not statements
of historical fact may be deemed forward-looking statements. The Company
cautions that these statements by their nature involve risks and uncertainties,
and actual results may differ materially depending on a variety of important
factors, including, but not limited to, the impact of competitive products,
pricing and new technology; changes in consumer preferences and tastes; and
effectiveness of marketing; changes in laws and regulations; fluctuations in
costs of production, and other factors as those discussed in the Company's
reports filed with the Securities and Exchange Commission from time to time. In
addition, the company disclaims any obligation to update any forward-looking
statements to reflect events or circumstances after the date hereof.

CONTACT:

Sunwin International Neutraceuticals
Tel: 877-China-57
Email: info@sunwin.biz